vs
Altimmune, Inc.（ALT）与Revolution Medicines, Inc.（RVMD）财务数据对比。点击上方公司名可切换其他公司
Altimmune, Inc.自由现金流更多（$-67.5M vs $-139.5M），过去两年Altimmune, Inc.的营收复合增速更高（128.0% vs -100.0%）
Altimmune是一家处于临床阶段的生物制药企业，专注于研发免疫疗法、疫苗及肽类疗法，管线覆盖传染病预防、肝脏疾病与代谢类疾病治疗领域，主要面向全球生物制药与医疗保健市场，推进候选药物的临床试验及后续商业化工作。
Tempus AI是美国健康科技企业，2015年由埃里克·莱夫科夫斯基在伊利诺伊州芝加哥创立，成立契机为其妻子确诊乳腺癌。公司依托数据与人工智能技术，为肿瘤、心脏病、放射医学、抑郁症等领域提供包含诊断在内的精准医疗服务，2024年6月14日于纳斯达克上市，股票代码为TEM。
ALT vs RVMD — 直观对比
营收规模更大
ALT
是对方的Infinity倍
$0
自由现金流更多
ALT
多$72.0M
$-139.5M
两年增速更快
ALT
近两年复合增速
-100.0%
损益表 — Q4 FY2025 vs Q4 FY2024
| 指标 | | |
|---|---|---|
| 营收 | $26.0K | $0 |
| 净利润 | — | $-194.6M |
| 毛利率 | — | — |
| 营业利润率 | — | — |
| 净利率 | — | — |
| 营收同比 | 420.0% | — |
| 净利润同比 | -18.0% | -20.4% |
| 每股收益（稀释后） | — | $-1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALTRVMD
| Q4 25 | $26.0K | — | ||
| Q3 25 | $5.0K | — | ||
| Q2 25 | $5.0K | — | ||
| Q1 25 | $5.0K | — | ||
| Q4 24 | $5.0K | $0 | ||
| Q3 24 | $5.0K | $0 | ||
| Q2 24 | $5.0K | $0 | ||
| Q1 24 | $5.0K | $0 |
净利润ALTRVMD
| Q4 25 | — | — | ||
| Q3 25 | $-19.0M | — | ||
| Q2 25 | $-22.1M | — | ||
| Q1 25 | $-19.6M | — | ||
| Q4 24 | — | $-194.6M | ||
| Q3 24 | $-22.8M | $-156.3M | ||
| Q2 24 | $-24.6M | $-133.2M | ||
| Q1 24 | $-24.4M | $-116.0M |
营业利润率ALTRVMD
| Q4 25 | — | — | ||
| Q3 25 | -417180.0% | — | ||
| Q2 25 | -458440.0% | — | ||
| Q1 25 | -436300.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -495340.0% | — | ||
| Q2 24 | -534900.0% | — | ||
| Q1 24 | -535880.0% | — |
净利率ALTRVMD
| Q4 25 | — | — | ||
| Q3 25 | -380280.0% | — | ||
| Q2 25 | -442920.0% | — | ||
| Q1 25 | -391500.0% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -456900.0% | — | ||
| Q2 24 | -492800.0% | — | ||
| Q1 24 | -487880.0% | — |
每股收益（稀释后）ALTRVMD
| Q4 25 | — | — | ||
| Q3 25 | $-0.21 | — | ||
| Q2 25 | $-0.27 | — | ||
| Q1 25 | $-0.26 | — | ||
| Q4 24 | — | $-1.13 | ||
| Q3 24 | $-0.32 | $-0.94 | ||
| Q2 24 | $-0.35 | $-0.81 | ||
| Q1 24 | $-0.34 | $-0.70 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $273.5M | $2.3B |
| 总债务越低越好 | $34.3M | — |
| 股东权益账面价值 | $224.9M | $2.3B |
| 总资产 | $279.9M | $2.6B |
| 负债/权益比越低杠杆越低 | 0.15× | — |
8季度趋势，按日历期对齐
现金及短期投资ALTRVMD
| Q4 25 | $273.5M | — | ||
| Q3 25 | $210.8M | — | ||
| Q2 25 | $183.1M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $131.9M | $2.3B | ||
| Q3 24 | $139.4M | $1.5B | ||
| Q2 24 | $164.9M | $1.6B | ||
| Q1 24 | $182.0M | $1.7B |
总债务ALTRVMD
| Q4 25 | $34.3M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ALTRVMD
| Q4 25 | $224.9M | — | ||
| Q3 25 | $185.6M | — | ||
| Q2 25 | $161.4M | — | ||
| Q1 25 | $142.2M | — | ||
| Q4 24 | $123.5M | $2.3B | ||
| Q3 24 | $133.4M | $1.6B | ||
| Q2 24 | $152.5M | $1.6B | ||
| Q1 24 | $172.9M | $1.7B |
总资产ALTRVMD
| Q4 25 | $279.9M | — | ||
| Q3 25 | $218.4M | — | ||
| Q2 25 | $190.3M | — | ||
| Q1 25 | $157.3M | — | ||
| Q4 24 | $139.3M | $2.6B | ||
| Q3 24 | $147.9M | $1.8B | ||
| Q2 24 | $173.3M | $1.8B | ||
| Q1 24 | $188.4M | $1.9B |
负债/权益比ALTRVMD
| Q4 25 | 0.15× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-67.5M | $-138.3M |
| 自由现金流经营现金流 - 资本支出 | $-67.5M | $-139.5M |
| 自由现金流率自由现金流/营收 | -259792.3% | — |
| 资本支出强度资本支出/营收 | 42.3% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-567.7M |
8季度趋势，按日历期对齐
经营现金流ALTRVMD
| Q4 25 | $-67.5M | — | ||
| Q3 25 | $-11.9M | — | ||
| Q2 25 | $-19.4M | — | ||
| Q1 25 | $-16.8M | — | ||
| Q4 24 | $-79.8M | $-138.3M | ||
| Q3 24 | $-27.1M | $-130.4M | ||
| Q2 24 | $-18.1M | $-128.2M | ||
| Q1 24 | $-16.4M | $-160.6M |
自由现金流ALTRVMD
| Q4 25 | $-67.5M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-139.5M | ||
| Q3 24 | — | $-133.9M | ||
| Q2 24 | — | $-130.6M | ||
| Q1 24 | — | $-163.7M |
自由现金流率ALTRVMD
| Q4 25 | -259792.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资本支出强度ALTRVMD
| Q4 25 | 42.3% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
